Cancer immune therapy using engineered ‛tail-flipping’ nanoliposomes targeting alternatively activated macrophages

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 2041-1723

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Cancer immune therapy using engineered ‛tail-flipping’ nanoliposomes targeting alternatively activated macrophages ; volume:13 ; number:1 ; day:4 ; month:8 ; year:2022 ; pages:1-17 ; date:12.2022
Nature Communications ; 13, Heft 1 (4.8.2022), 1-17, 12.2022

Creator: Kuninty, Praneeth R.
Binnemars-Postma, Karin
Jarray, Ahmed
Pednekar, Kunal P.
Heinrich, Marcel A.
Pijffers, Helen J.
Hoopen, Hetty ten
Storm, Gert
Hoogevest, Peter van
Otter, Wouter K. den
Prakash, Jai

Contributor: SpringerLink (Online service)

DOI: 10.1038/s41467-022-32091-9

URN: urn:nbn:de:101:1-2022101921535135252372

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 2025-08-15T07:29:09+0200

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Kuninty, Praneeth R.
Binnemars-Postma, Karin
Jarray, Ahmed
Pednekar, Kunal P.
Heinrich, Marcel A.
Pijffers, Helen J.
Hoopen, Hetty ten
Storm, Gert
Hoogevest, Peter van
Otter, Wouter K. den
Prakash, Jai
SpringerLink (Online service)

Other Objects (12)

Therapeutic Targeting of Hepatic Macrophages

Differential sensitivity of inflammatory macrophages and alternatively activated macrophages to ferroptosis

Hochschulschrift

Analysis of translation in early activated macrophages

Hochschulschrift

Targeting of activated macrophages through CD64 to elucidate their role in the pathogenesis of Multiple sclerosis

Engineered CD147-CAR macrophages for enhanced phagocytosis of cancers

Mmu-miR-125b overexpression suppresses NO production in activated macrophages by targeting eEF2K and CCNA2

Engineered Methyltransferase-Catalyzed Terminal Prenyl Group Tail Methylation of Linear Terpenoids

Targeting tauopathy with engineered tau-degrading intrabodies

Hochschulschrift

Transcriptional and epigenetic regulation of differentially activated macrophages

Hochschulschrift

Targeting immunotoxins to activated T-lymphocytes

Targeting tumor-associated macrophages for cancer treatment

Advances in Engineered Macrophages: A New Frontier in Cancer Immunotherapy

Therapeutic Targeting of Hepatic Macrophages

Differential sensitivity of inflammatory macrophages and alternatively activated macrophages to ferroptosis

Hochschulschrift

Analysis of translation in early activated macrophages

Hochschulschrift

Targeting of activated macrophages through CD64 to elucidate their role in the pathogenesis of Multiple sclerosis

Engineered CD147-CAR macrophages for enhanced phagocytosis of cancers

Mmu-miR-125b overexpression suppresses NO production in activated macrophages by targeting eEF2K and CCNA2

Engineered Methyltransferase-Catalyzed Terminal Prenyl Group Tail Methylation of Linear Terpenoids

Targeting tauopathy with engineered tau-degrading intrabodies

Hochschulschrift

Transcriptional and epigenetic regulation of differentially activated macrophages

Hochschulschrift

Targeting immunotoxins to activated T-lymphocytes

Targeting tumor-associated macrophages for cancer treatment

Advances in Engineered Macrophages: A New Frontier in Cancer Immunotherapy

Therapeutic Targeting of Hepatic Macrophages

Differential sensitivity of inflammatory macrophages and alternatively activated macrophages to ferroptosis

Hochschulschrift

Analysis of translation in early activated macrophages

Hochschulschrift

Targeting of activated macrophages through CD64 to elucidate their role in the pathogenesis of Multiple sclerosis

Engineered CD147-CAR macrophages for enhanced phagocytosis of cancers

Mmu-miR-125b overexpression suppresses NO production in activated macrophages by targeting eEF2K and CCNA2

Engineered Methyltransferase-Catalyzed Terminal Prenyl Group Tail Methylation of Linear Terpenoids

Targeting tauopathy with engineered tau-degrading intrabodies

Hochschulschrift

Transcriptional and epigenetic regulation of differentially activated macrophages

Hochschulschrift

Targeting immunotoxins to activated T-lymphocytes

Targeting tumor-associated macrophages for cancer treatment

Advances in Engineered Macrophages: A New Frontier in Cancer Immunotherapy

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Cancer immune therapy using engineered ‛tail-flipping’ nanoliposomes targeting alternatively activated macrophages

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Therapeutic Targeting of Hepatic Macrophages

Differential sensitivity of inflammatory macrophages and alternatively activated macrophages to ferroptosis

Analysis of translation in early activated macrophages

Targeting of activated macrophages through CD64 to elucidate their role in the pathogenesis of Multiple sclerosis

Engineered CD147-CAR macrophages for enhanced phagocytosis of cancers

Mmu-miR-125b overexpression suppresses NO production in activated macrophages by targeting eEF2K and CCNA2

Engineered Methyltransferase-Catalyzed Terminal Prenyl Group Tail Methylation of Linear Terpenoids

Targeting tauopathy with engineered tau-degrading intrabodies

Transcriptional and epigenetic regulation of differentially activated macrophages

Targeting immunotoxins to activated T-lymphocytes

Targeting tumor-associated macrophages for cancer treatment

Advances in Engineered Macrophages: A New Frontier in Cancer Immunotherapy

Therapeutic Targeting of Hepatic Macrophages

Differential sensitivity of inflammatory macrophages and alternatively activated macrophages to ferroptosis

Analysis of translation in early activated macrophages

Targeting of activated macrophages through CD64 to elucidate their role in the pathogenesis of Multiple sclerosis

Engineered CD147-CAR macrophages for enhanced phagocytosis of cancers

Mmu-miR-125b overexpression suppresses NO production in activated macrophages by targeting eEF2K and CCNA2

Engineered Methyltransferase-Catalyzed Terminal Prenyl Group Tail Methylation of Linear Terpenoids

Targeting tauopathy with engineered tau-degrading intrabodies

Transcriptional and epigenetic regulation of differentially activated macrophages

Targeting immunotoxins to activated T-lymphocytes

Targeting tumor-associated macrophages for cancer treatment

Advances in Engineered Macrophages: A New Frontier in Cancer Immunotherapy

Therapeutic Targeting of Hepatic Macrophages

Differential sensitivity of inflammatory macrophages and alternatively activated macrophages to ferroptosis

Analysis of translation in early activated macrophages

Targeting of activated macrophages through CD64 to elucidate their role in the pathogenesis of Multiple sclerosis

Engineered CD147-CAR macrophages for enhanced phagocytosis of cancers

Mmu-miR-125b overexpression suppresses NO production in activated macrophages by targeting eEF2K and CCNA2

Engineered Methyltransferase-Catalyzed Terminal Prenyl Group Tail Methylation of Linear Terpenoids

Targeting tauopathy with engineered tau-degrading intrabodies

Transcriptional and epigenetic regulation of differentially activated macrophages

Targeting immunotoxins to activated T-lymphocytes

Targeting tumor-associated macrophages for cancer treatment

Advances in Engineered Macrophages: A New Frontier in Cancer Immunotherapy

Related objects

Reset password